This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Hematology				
Sickle cell disease	Histone deacetylase (HDAC)	Studies in mice suggest that HDAC inhibitors could help treat sickle cell disease. In transgenic sickle cell mice, the HDAC inhibitor trichostatin A reduced levels of vascular cell adhesion molecule-1 (VCAM-1) and tissue factor (TF)—two indicators of sickle cell disease–related vasculature dysfunction—compared with vehicle control. Next steps could include long-term testing of HDAC inhibitors in the sickle cell disease mouse model. Merck & Co. Inc. markets Zolinza vorinostat (SAHA) to treat cutaneous T cell lymphoma (CTCL). *SciBX* 3(5); doi:10.1038/scibx.2010.150 Published online Feb. 4, 2010	Patent and licensing status unavailable	Hebbel, R. *et al. Blood*; published online Jan. 6, 2010; doi:10.1182/blood-2009-02-204990 **Contact:** Robert P. Hebbel, University of Minnesota, Minneapolis, Minn. e-mail: hebbe001@umn.edu